Drug Profile
UE 2343
Alternative Names: UE-2343; XanamemLatest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator University of Edinburgh
- Developer Actinogen Medical
- Class Antidementias; Azabicyclo compounds; Ketones; Pyrazoles; Pyrimidines; Small molecules; Thiophenes
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Major depressive disorder
- Preclinical Fragile X syndrome
Most Recent Events
- 24 Jan 2024 Efficacy and adverse events data from a phase I PET target occupancy trial in Alzheimer's disease released by Actinogen Medical
- 13 Oct 2023 Actinogen Medical plans a XanaMIA phase IIb trial for Alzheimer’s disease (Early-stage disease) in Australia in the first half of 2023
- 28 Aug 2023 Chemical structure information added